Treatment Sequencing in EGFR-Mutant NSCLC

Panelists discuss how anticipating resistance mechanisms such as C797S mutation or MET amplification is essential when designing first-line strategies. Selecting agents with favorable resistance profiles can prolong disease control and preserve future treatment options.

They explore sequencing pathways, outlining preferred strategies following progression on various regimens, including osimertinib or amivantamab–lazertinib. The panel underscores that molecular reevaluation at progression is critical to guide subsequent therapies, including targeted combinations or chemotherapy-based regimens.

Thoughtful sequencing not only maximizes overall survival but also minimizes unnecessary toxicity. Planning enables clinicians to map out multiline strategies that align with each patient’s molecular evolution and clinical needs.